Property:Results after intervention
This is a property of type Text.
J
Johnson et al. (2010): Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain +
NA +
Jyothirmayi et al. (1996): Efficacy of Vitamin A in the Prevention of Locoregional Recurrence and Second Primaries in Head and Neck Cancer +
- Intervention group 20% vs. placebo group 10%
- According to authors no significant differences (no p-value given) +
Jyothirmayi et al. (1996): Efficacy of Vitamin A in the Prevention of Locoregional Recurrence and Second Primaries in Head and Neck Cancer +
- None in intervention group
- Two in placebo group (1 case of tongue cancer and 1 of floor of mouth cancer)
- No p-values reported +
Jyothirmayi et al. (1996): Efficacy of Vitamin A in the Prevention of Locoregional Recurrence and Second Primaries in Head and Neck Cancer +
Mean (μg/ml) after three years
- intervention group: 0.78
- placebo group: 0.5
- no p-values reported +
K
Karp et al. (2012): Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597 +
Selenium level at baseline (n=1,022), year 2 (n=375), and year 4 (n=194): at baseline selenium level mostly in normal range, after 2 and 4 years significantly increased selenium concentration in the intervention arm +
Karp et al. (2012): Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597 +
Intervention arm: 76.8% (SE, 1.6%) vs. placebo arm: 79.9% (SE, 2.1%); p=0.154
Note: Distribution significantly different for smoking status (p=0.027): active smokers or those who had quit within one year showed a 3-year OS of 85.5% (SE, 1.7%) and 5-year OS of 74.9% (SE, 2.4%), whereas participants who had never smoked showed a 3-year OS of 90% (SE, 2.8%) and a 5-year OS of 83.6% (SE, 3.6%); no difference for DFS; p=0.245 +
Karp et al. (2012): Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597 +
Collected in 865 patients in intervention arm and 477 in placebo arm:
* Grade 1-2 toxicity in intervention arm: 31% and placebo arm: 26% of subjects
* Grade ≥ 3 toxicity occurred in less than 2% of subjects in intervention arm and 3% in placebo arm
* n=1 patient in placebo arm had constitutional lethal toxicity
* no arm comparison performed +
Karp et al. (2012): Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597 +
Interim analysis October 2009:
N=83 secondary lung tumors; Rate intervention arm: 1.91 per 100 persons per year vs. 1.36 in placebo arm; p=ns
June 2011:
N=252 secondary tumors in 224 patients, of which 98 (out of 97 patients) were lung cancer (38.9%); Lung cancer and other cancers (SPT) in intervention arm: 1.62 and 3.54 per 100 persons per year vs. placebo arm: 1.30 and 3.39 per 100 persons per year; p=0.294
5-year DFS:
October 2009:
Intervention arm: 72% vs. placebo arm: 78%, no significance values given
June 2011:
Intervention arm: 74.4% vs. placebo arm: 79.6%; p=0.69
Note: 5-year DFS rates with subdivision into low, average and high selenium concentration intervention vs. placebo: 75.5% (SE, 10.3%) vs. 72.9% (SE, 12.7%), 75.6% (SE, 2.27%) vs. 78.2% (SE, 3.3%), and 72.9% (SE, 4.5%) vs. 80.9% (SE, 5.2%) +
Kasseroller et al. (2003): Efficacy and tolerability of proteolytic enzymes as an anti-inflammatory agent in lymphoedema after axillary dissection due to mammary cancer +
Mean tension of the ill arm after 45 days:
Enzyme-arm = 0.4;
Placebo-arm = 0.5
Both arms show a similar decrease of tension in the ill arm, but but the decrease was a little bit greater in the enzyme-arm (p=NI). +
Kasseroller et al. (2003): Efficacy and tolerability of proteolytic enzymes as an anti-inflammatory agent in lymphoedema after axillary dissection due to mammary cancer +
Mean volume of the upper ill arm at day 45:
Enzyme-arm = 4mm;
Placebo-arm = 3.4mm
Both arms show similiar developement of skin thickness after 45 days. Similar development in the lower arm, hand and third finger. There is a slight advantage for the enzyme-arm for upper ill arm and lower arm; (p=NI). +
Kasseroller et al. (2003): Efficacy and tolerability of proteolytic enzymes as an anti-inflammatory agent in lymphoedema after axillary dissection due to mammary cancer +
Mean Volometer of the ill arm at day 45:
Enzyme-arm = 2275.1;
Placebo-arm = 2225.7
Both arms show a decrease of volume until day 45, but there was no significant difference between the arms (p = NI). +
Keshavarzi et al. (2019): The effect of vitamin D and E vaginal suppositories on tamoxifen-induced vaginal atrophy in women with breast cancer +
NI +
Kessels et al. (2017): Topical Sinecatechins, 10%, Ointment for Superficial Basal Cell Carcinoma A Randomized Clinical Trial +
Complete histological tumor clearance was observed in 1 of 21 (5%) and 2 of 21 (10%) patients in the sinecatechins and placebo group, respectively no significant difference in histological tumor clearance between the sinecatechins and placebo groups (p > .99). +
Kessels et al. (2017): Topical Sinecatechins, 10%, Ointment for Superficial Basal Cell Carcinoma A Randomized Clinical Trial +
Decrease in tumor size was slightly greater after sinecatechins application, but the difference was nonsignificant (p = 0.15). +
Khan et al. (2017): Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial +
NI +
Khan et al. (2017): Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial +
NI +
Khan et al. (2017): Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial +
NI +
Khan et al. (2017): Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial +
NI +
Khan et al. (2017): Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial +
NI +
Khodabakhshi et al. (2019): Feasibility, Safety, and Beneficial Effects of MCT-Based Ketogenic Diet for Breast Cancer Treatment: A Randomized Controlled Trial Study +
Significant effect only for subgroup: overall survival was higher in intervention arm compared to comparison arm for patients undergoing neoadjuvant treatment (p=0.04) after 3 months
n = 25 (intervention) + 19 (comparison) +